A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

• Status: Completed
• Trial end date: 2016-02-04
• Target enrollment: 0
• Participant gender: All

Summary

To determine the dose or doses of PF-00547659 that will be the most effective to improve or halt the disease symptoms in patients with moderate to severe ulcerative colitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Shire

Criteria

Inclusion Criteria:

• Subjects with diagnosis of Ulcerative Colitis for 3 or more months.

• Ulcerative colitis must be active beyond the rectum.

• Must active Ulcerative Colitis with a Total Mayo Score of 6 to 12 points

Exclusion Criteria:

• Pregnant or breast feeding.

• Diagnosis of indeterminate colitis or Crohn's Disease

• Subjects with history of colonic or small bowel obstruction or resection.